

## INHERITED EYE DISORDERS TESTING REQUISITION

### PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)

Patient Last Name	Patient First Name	MI	Date of Birth (MM/DD/YY)
Address		Accession #	Hospital/ Medical Record #
City	State	Zip	Phone
			Biological Sex: <input type="radio"/> M <input type="radio"/> F <input type="radio"/> Unknown
Gender identity (if different from above):			

### REPORTING RECIPIENTS

Ordering Physician	Institution Name
Email (Required for International Clients)	Phone
<b>ADDITIONAL RECIPIENTS</b>	Fax

Name	Name
Email	Email
Fax	Fax

### PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)

**SELF PAYMENT**

Bill Patient For Laboratory Testing

**INSTITUTIONAL BILLING**

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

**INSURANCE**

Do Not Perform Test Until Patient is Aware of Out-Of-Pocket Costs (excludes prenatal testing)

**REQUIRED ITEMS** 1. Copy of the Front/Back of Insurance Card(s)  
 2. ICD10 Diagnosis Code(s)  
 3. Name of Ordering Physician  
 4. Insured Signature of Authorization

Name of Insured	Insured Date of Birth (MM/DD/YY)	Address of Insured
Patient's Relationship to Insured	Phone of Insured	City
Primary Insurance Co. Name	Primary Insurance Co. Phone	Primary Member Policy #
Secondary Insurance Co. Name	Secondary Insurance Co. Phone	Secondary Member Policy #
		Primary Member Group #
		Secondary Member Group #

By signing below, I hereby authorize Baylor Genetics to provide my designated insurance carrier any information necessary, including test results, for processing my insurance claim. I also authorize benefits to be payable exclusively to Baylor Genetics. I understand that my insurance carrier may not approve or reimburse my medical genetic services in full or any portion thereof, due to a variety of reasons, including, but not limited to: the contract status of my insurance provider with Baylor Genetics, usual and customary rate limits, benefit exclusions, coverage limits, lack of authorization, or medical necessity. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates. I understand that I am responsible for any amounts not paid by my insurance carrier for reasons including, but not limited to, non-covered and non-authorized services. I understand that I am responsible for sending Baylor Genetics, any and all payments that I receive directly from my insurance company in payment for this test. Please note that Medicare does not cover routine screening tests.

Patient's Name	Patient's Signature	Date
----------------	---------------------	------

### STATEMENT OF MEDICAL NECESSITY (REQUIRED)

This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient and they have consented to genetic testing.

Physician's Printed Name	Physician's Signature	Date
--------------------------	-----------------------	------

## INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM/DD/YY) \_\_\_\_\_ Biological Sex \_\_\_\_\_

### ETHNICITY

- |  |   |  |
|--|---|--|
| <input type="radio"/> African American                 | <input type="radio"/> Mennonite   | <input type="radio"/> Southeast Asian (Vietnam, Cambodia, Thailand)      |
| <input type="radio"/> Ashkenazi Jewish                 | <input type="radio"/> Middle Eastern (Saudi Arabia, Qatar, Iraq, Turkey)              | <input type="radio"/> Southern European Caucasian (Spain, Italy, Greece) |
| <input type="radio"/> East Asian (China, Japan, Korea) | <input type="radio"/> Native American   | <input type="radio"/> Other (Specify) _____                              |
| <input type="radio"/> Finnish                          | <input type="radio"/> Northern European Caucasian (Scandinavian, UK, Germany)         |  |
| <input type="radio"/> French Canadian                  | <input type="radio"/> Pacific Islander (Philippines, Micronesia, Malaysia, Indonesia) |  |
| <input type="radio"/> Hispanic American                | <input type="radio"/> South Asian (India, Pakistan)                                   |  |

### INDICATION FOR TESTING (REQUIRED)

- Symptomatic (Summarize below)  Symptomatic with Family History  
 \_\_\_\_\_  
 Asymptomatic  
 Population Screening  
 Positive Family History

Disease \_\_\_\_\_ Gene \_\_\_\_\_ Variant \_\_\_\_\_  
 ICD10 Diagnosis Code(s): \_\_\_\_\_

### SAMPLE

#### SAMPLE TYPE

- |   |                                       |
|---|---------------------------------------|
| <input type="radio"/> Blood in EDTA-tube (purple-top)   | <input type="radio"/> Liver           |
| <input type="radio"/> Blood in Heparin-tube (green-top) | <input type="radio"/> Saliva          |
| <input type="radio"/> DNA                               | <input type="radio"/> Skeletal Muscle |
| <input type="radio"/> Other (Specify) _____             | <input type="radio"/> Tissue          |

Note: Blood should not be sent from patients who have had a bone marrow transplant or recent blood transfusion

\_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
 Date of Collection (MM/DD/YY)

### TESTING OPTIONS

- Targeted Sequencing for Known Familial Mutation  
 (If selected, specify test code and gene below and complete section to the right)  
 Test Code \_\_\_\_\_ Gene \_\_\_\_\_  
 Full Gene Sequencing  
 Deletion/ Duplication Analysis

#### FOR TARGETED TESTING SELECTION ONLY

Proband Last Name \_\_\_\_\_ Proband First Name \_\_\_\_\_  
 \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
 Date of Birth (MM/DD/YY) Relationship of Proband to Patient \_\_\_\_\_  
 Proband testing location (Select one)  
 Baylor Genetics Lab # \_\_\_\_\_ Family # \_\_\_\_\_  
 Another laboratory 1. Attach a copy of the Proband test results  
 2. A positive control sample of the Proband is requested.  
 Please provide, if available.

### INHERITED EYE DISORDERS TESTS

#### CYTOGENETIC TESTS

TEST CODE	TEST NAME	SAMPLE TYPE *	SPECIFY GENE OF INTEREST	SPECIFY REGION OF INTEREST
<input type="checkbox"/> 8665	Chromosomal Microarray Analysis (CMA) - HR + SNP Screen (Comprehensive)	BE + BH		
<input type="checkbox"/> 8655	Chromosomal Microarray Analysis (CMA) - HR	BE + BH		

#### MITOCHONDRIAL DNA (mtDNA) MUTATION SCREENS

TEST CODE	TEST NAME	SAMPLE TYPE *
<input type="checkbox"/> 2010	Advanced mtDNA Point Mutations and Deletions by Massively Parallel Sequencing (BCM-MitomeNGS <sup>SM</sup> )	BE, SM, T
<input type="checkbox"/> 2055	Comprehensive mtDNA Analysis by Massively Parallel Sequencing (BCM-MitomeNGS <sup>SM</sup> )	BE, DNA, L SM, T

\* Refer to Sample Specifications Table (page 5)

## INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM/DD/YY) \_\_\_\_\_ Biological Sex \_\_\_\_\_

### INHERITED EYE DISORDERS TESTS

#### MASSIVELY PARALLEL SEQUENCING (BCM-MitomeNGS<sup>SM</sup>) PANELS

TEST CODE	TEST NAME	SAMPLE TYPE *	TEST CODE	TEST NAME	SAMPLE TYPE *
<input type="checkbox"/> 20100	Albinism Panel (13 genes)	BE, DNA	<input type="checkbox"/> 5255	Primary Open Angle Glaucoma Panel ( <i>MYOC, OPTN</i> )	BE, DNA
<input type="checkbox"/> 5260	Developmental Glaucoma Panel (8 genes)	BE, DNA	<input type="checkbox"/> 2140	Progressive External Ophthalmoplegia Panel (10 genes)	BE, DNA
<input type="checkbox"/> 5250	Familial Exudative Vitreoretinopathy Panel ( <i>FZD4, LRP5, NDP, and TSPAN12</i> )	BE, DNA	<input type="checkbox"/> 2190	Retinitis Pigmentosa + RPGR orf15 by NGS (66 genes)	BE, DNA
<input type="checkbox"/> 5090	Leber Congenital Amaurosis Panel (19 genes)	BE, DNA	<input type="checkbox"/> 2195	Usher Syndrome Panel (9 genes)	BE, DNA

#### DNA COPY NUMBER ANALYSIS

TEST CODE	TEST NAME	SAMPLE TYPE *	SPECIFY GENE OF INTEREST			
<input type="checkbox"/> 2000	MitoMet <sup>®</sup> Plus aCGH Analysis	BE				
<input type="checkbox"/> 2001	Oligonucleotide Targeted Array Analysis (Single Target Gene)	BE				
<input type="checkbox"/> 2003	Oligonucleotide Targeted Array Analysis (Up to 5 Target Genes)	BE				

#### SINGLE GENE ANALYSIS

If a test is not found on this form, please obtain the test code from our website ([www.BMGL.com](http://www.BMGL.com)) and write in the below space(s).

Test Code \_\_\_\_\_ Gene \_\_\_\_\_ Test Code \_\_\_\_\_ Gene \_\_\_\_\_ Test Code \_\_\_\_\_ Gene \_\_\_\_\_

Test Name \_\_\_\_\_ Test Name \_\_\_\_\_ Test Name \_\_\_\_\_

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
<input type="checkbox"/> 6603	<i>ABCA4</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>ABCA4</i> -Related Disorders	BE
<input type="checkbox"/> 2924	<i>BEST1</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>BEST1</i> -Related Disorders	BE
<input type="checkbox"/> 2419	<i>CEP290</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>CEP290</i> -Related Disorders	BE
<input type="checkbox"/> 6655	<i>CDH23</i> Sequence Analysis	<i>CDH23</i> -Related Disorders	BE
<input type="checkbox"/> 6660	<i>CLRN1</i> Sequence Analysis	<i>CLRN1</i> -Related Disorders	BE
<input type="checkbox"/> 7521	<i>COL2A1</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>COL2A1</i> -Related Disorders	BE
<input type="checkbox"/> 2389	<i>CDHR1</i> Comprehensive (Seq. & Del/Dup Analysis)	Cone-Rod Dystrophy 15	BE
<input type="checkbox"/> 2849	<i>CRB1</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>CRB1</i> -Related Disorders	BE
<input type="checkbox"/> 2954	<i>CRX</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>CRX</i> -Related Disorders	BE
<input type="checkbox"/> 29215	<i>CYP11B1</i> Sequence Analysis by NGS	<i>CYP11B1</i> -Related Disorders	BE, DNA
<input type="checkbox"/> 29260	<i>TSPAN12</i> Sequence Analysis by NGS	Exudative Vitreoretinopathy 5	BE, DNA
<input type="checkbox"/> 29255	<i>FZD4</i> Sequence Analysis by NGS	<i>FZD4</i> -Related Disorders	BE, DNA
<input type="checkbox"/> 2439	<i>GUCY2D</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>GUCY2D</i> -Related Disorders	BE
<input type="checkbox"/> 5280	<i>OAT</i> Sequence Analysis	Gyrate Atrophy of Choroid and Retina	BE
<input type="checkbox"/> 2789	<i>IMPDH1</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>IMPDH1</i> -Related Disorders	BE
<input type="checkbox"/> 2394	<i>LCA5</i> Comprehensive (Seq. & Del/Dup Analysis)	<i>LCA5</i> -Related Disorders	BE

\* Refer to Sample Specifications Table (page 5)

Continued on next page

## INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM/DD/YY) \_\_\_\_\_ Biological Sex \_\_\_\_\_

### SINGLE GENE ANALYSIS CONTINUED

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
<input type="checkbox"/> 5084	<i>CABP4</i> Comprehensive (Seq. & Del/Dup Analysis)	Leber Congenital Amaurosis	BE
<input type="checkbox"/> 5069	<i>IQCB1</i> Comprehensive (Seq. & Del/Dup Analysis)	Leber Congenital Amaurosis	BE
<input type="checkbox"/> 6039	<i>OCRL</i> Sequence Analysis	Lowe Syndrome	BE
<input type="checkbox"/> 2839	<i>LRAT</i> Comprehensive (Seq. & Del/Dup Analysis)	LRAT-Related Disorders	BE
<input type="checkbox"/> 29265	<i>LRP5</i> Sequence Analysis by NGS	LRP5-Related Disorders	BE, DNA
<input type="checkbox"/> 2409	<i>MFRP</i> Comprehensive (Seq. & Del/Dup Analysis)	Microphthalmia, Isolated 5 Disorder	BE
<input type="checkbox"/> 29270	<i>NDP</i> Sequence Analysis by NGS	NDP-Related Disorders	BE, DNA
<input type="checkbox"/> 6083	X-Linked, <i>GPR143</i> Comprehensive (Seq. & Del/Dup Analysis)	Oculocutaneous Albinism	BE
<input type="checkbox"/> 3469	Type 1, <i>OPA1</i> Comprehensive (Seq. & Del/Dup Analysis)	Optic Atrophy	BE
<input type="checkbox"/> 3529	Type 3, <i>OPA3</i> Comprehensive (Seq. & Del/Dup Analysis)	Optic Atrophy	BE
<input type="checkbox"/> 29250	<i>OPTN</i> Sequence Analysis by NGS	OPTN-Related Disorders	BE, DNA
<input type="checkbox"/> 29235	<i>PAX6</i> Sequence Analysis by NGS	PAX6-Related Disorders	BE, DNA
<input type="checkbox"/> 29240	<i>PITX2</i> Sequence Analysis by NGS	PITX2-Related Disorders	BE, DNA
<input type="checkbox"/> 29220	<i>PITX3</i> Sequence Analysis by NGS	PITX3-Related Disorders	BE, DNA
<input type="checkbox"/> 2414	<i>ABHD12</i> Comprehensive (Seq. & Del/Dup Analysis)	Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa, and Cataract Disorder	BE
<input type="checkbox"/> 29245	<i>MYOC</i> Sequence Analysis by NGS	Primary Open Angle Glaucoma 1A	BE, DNA
<input type="checkbox"/> 2959	<i>RDH12</i> Comprehensive (Seq. & Del/Dup Analysis)	RDH12-Related Disorders	BE
<input type="checkbox"/> 2964	<i>C2orf71</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2764	<i>CA4</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2944	<i>CNGB1</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2969	<i>DHDDS</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2974	<i>EYS</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2994	<i>FAM161A</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2769	<i>FSCN2</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2454	<i>IMPG2</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2984	<i>MERTK</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2459	<i>PDE6B</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2399	<i>PROM1</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2799	<i>PRPF31</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2939	<i>PRPH2</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2479	<i>RGR</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2474	<i>RLBP1</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2814	<i>ROM1</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2449	<i>RP2</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2359	<i>RPGR</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2484	<i>SAG</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE
<input type="checkbox"/> 2894	<i>TOPORS</i> Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE

\* Refer to Sample Specifications Table (page 5)

Continued on next page

**INHERITED EYE DISORDERS TESTING REQUISITION**

 Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ / / \_\_\_\_\_  
 Date of Birth (MM/DD/YY) \_\_\_\_\_ Biological Sex \_\_\_\_\_

**SINGLE GENE ANALYSIS CONTINUED**

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE *
<input type="checkbox"/> 29540	RS1 Sequence Analysis by NGS	Retinoschisis	BE, DNA
<input type="checkbox"/> 2934	RPE65 Comprehensive (Seq. & Del/Dup Analysis)	RPE65-Related Disorders	BE, DNA
<input type="checkbox"/> 2354	RPGRIP1 Comprehensive (Seq. & Del/Dup Analysis)	RPGRIP1-Related Disorders	BE, DNA
<input type="checkbox"/> 2899	PRKCG Comprehensive (Seq. & Del/Dup Analysis)	Spinocerebellar Ataxia 14 (SCA)	BE, DNA
<input type="checkbox"/> 6650	USH2A Sequence Analysis	USH2A-Related Disorders	BE, DNA
<input type="checkbox"/> 2379	Type 1C, USH1C Comprehensive (Seq. & Del/Dup Analysis)	Usher Syndrome	BE, DNA
<input type="checkbox"/> 2374	Type 1F, PCDH15 Comprehensive (Seq. & Del/Dup Analysis)	Usher Syndrome	BE, DNA
<input type="checkbox"/> 2369	Type 2C, GPR98 Comprehensive (Seq. & Del/Dup Analysis)	Usher Syndrome	BE, DNA
<input type="checkbox"/> 2364	Type 2D, DFNB31 Comprehensive (Seq. & Del/Dup Analysis)	Usher Syndrome	BE, DNA
<input type="checkbox"/> 29230	VSX1 Sequence Analysis	VSX1-Related Disorders	BE, DNA

\* Refer to Sample Specifications Table below

**SAMPLE SPECIFICATIONS TABLE**

ABBREVIATION	SAMPLE NAME	RECOMMENDED AMOUNT		SHIPPING INSTRUCTIONS	SPECIAL NOTES
		(2 yrs - Adult)	(Newborn - 2 yrs)		
BE	Blood in EDTA tube (purple-top)	10 cc	2 -3 cc	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	
BH	Blood in Sodium Heparin tube (green-top)	3 - 5 cc	1 - 2 cc	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	
DNA	DNA, Extracted	10 - 15 ug	10 - 15 ug	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Minimal concentration of 50ng/uL; A260/A280 of ~1.7
L	Liver	10 - 15 mg	10 - 15 mg	Ship frozen sample in insulated container, with 3 -5 lbs dry ice, by overnight courier.	Liver should be flash frozen in liquid nitrogen at collection with no media added and stored at -80°C.
SA	Saliva	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Collected with Oragene DNA Self-Collection Kit.
SM	Skeletal Muscle	150 mg	150 mg	Ship frozen sample in insulated container, with 3 -5 lbs dry ice, by overnight courier.	Skeletal Muscle should be flash frozen in liquid nitrogen at collection with no media added, and stored at -80°C.
T	Tissue	50 mg	50 mg	Ship frozen sample in insulated container, with 3 -5 lbs dry ice, by overnight courier.	Tissue should be flash frozen in liquid nitrogen at collection with no media added, and stored at -80°C.